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Introduction: To prospectively evaluate quantitative assessment of fluorescence optical imaging (FOI) for
differentiation of synovitic from non-synovitic joints in patients suffering from rheumatoid arthritis (RA).
Methods: FOI of the hands was performed in patients with active RA, and a stratified quantitative fluorescence
readout (FLRO) of 3 phases (1-120 s; 121-240 s; 241-360 s) was generated for 5 individual joints of the clinical
predominant hand (carpal joint, metacarpophalangeal and proximal interphalangeal joints of digits II & III). To
dissect the effect of the overall perfusion of the hand from the perfusion due to synovitis, a fluorescence ratio
(FLRA) was additionally calculated, dividing each FLRO by the readout of the eponychium of digit II. The mean
FLRO and FLRA were compared between joints with absent vs. present synovitis determined by clinical
examination, grayscale, color Doppler ultrasonography, or magnetic resonance imaging (MRI).
Results: The analysis for 90 individual joints from 18 patients yielded FLRO ranging from 4.4 to 49.0 × 103, and
FLRAs ranging from 0.37 to 2.27. Overall, the analyses based on the FLRA revealed a higher discrimination than the
analyses related to the FLRO, demonstrating most significant differences in phases 2 and 3. A sensitivity of 26/39
(67%) and a specificity of 31/40 (77%) were calculated for FLRA of phase 3 using a cut-off value of more than 1.2 to
detect MRI-confirmed synovitis with FOI.
Conclusions: FOI has a potential for visualizing synovitis in subjects with RA. For adequate FOI interpretation,
quantitative analysis should be based on the novel FLRA calculated for phases 2 and 3.Introduction
Rheumatoid arthritis (RA) is an inflammatory disorder
involving multiple joints [1,2]. It is the most common
chronic inflammatory joint disease with a prevalence of
0.5 to 1.0% [3,4]. Persistent synovitis leads to massive joint
destruction, and eventually causes irreversible disability in
patients. It is of uttermost importance to recognize early
synovitis, before substantial joint damage occurs and to
start early and aggressive therapy in order to improve
short- and long-term outcomes [5-7]. Therefore, sensitive
and specific tools for early diagnosis of RA are necessary
[5,6]. The clinical examination (CE) is a prerequisite, but
may miss subclinical inflammation in patients with early* Correspondence: va.schaefer@asklepios.com
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reproduction in any medium, provided the ordisease as well as in those who are in clinical remission
under treatment [8]. Conventional x-ray examination is
often used as an indicator of prognosis and represents the
standard outcome measure of disease progression, but does
not display the current disease activity [9]. Ultrasonography
(US) is a valid tool in the assessment of patients with
synovitis and in scoring the clinical activity [10-12]. US
is, however, a time-consuming, and operator-dependent
technique and might miss signs of early arthritis [13-15].
Magnetic resonance imaging (MRI) has proven to be the
strongest independent predictor of radiographic progres-
sion in patients with RA [5,9]. MRI, however, is costly,
time-consuming, and not ubiquitously available. For fast
and dynamic assessment of joint inflammation, US is more
widely available than MRI in daily clinical practice [16].
The disadvantage of US is that it is a time-consuming
method, and, apart from in clinical studies, the examinationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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time constraints.
Fluorescence optical imaging (FOI) is a new, non-
invasive and non-ionizing imaging technology with fast
acquisition times [17,18]. The major drawback of FOI
is the limited tissue penetration of light; however, as
inflammatory arthopathies typically affect the small joints
of the hands and feet, this is not necessarily a significant
limitation for this imaging method [19]. Under various ex-
perimental conditions, FOI proved to correspond to syno-
vitis [17,18,20-24]. In those experiments, early hyperemia
of inflamed joints could be diagnosed by recording
scattering and absorption patterns of light transmitted
through inflamed finger joints. This approach has already
been tested in humans [21,25], which led to the develop-
ment of an FOI system with fixed optical geometry (Xiralite
X4; Mivenion GmbH, Berlin, Germany). The fluorescent
dye indocyanine green (ICG) appears to be an appropriate
tracer, because it has been shown to enhance inflamed
joints [20,26]. Furthermore, this substance has been
approved by the Federal Drugs Administration. In a
study by Scheel et al. [27] FOI provided information
about the inflammation status of finger joints with a
sensitivity and specificity of 80% and 89%, respectively.
In a clinical study by Werner et al. [8] FOI had, taking
MRI as a reference, a sensitivity of 76% and a specificity of
54%. Recently, another study by Meier et al. [19] reported
that FOI had a sensitivity of 39.6% and a specificity of
85.2%, compared with MRI demonstrating conflicting
results regarding the reliability of this new method. In
2011 Dziekan et al. [28] proposed a quantitative analysis
of FOI using normalized variances of fluorescence time
correlation functions. In their pivotal pilot study, the
joints of healthy volunteers and patients with RA were
compared, but no other imaging techniques besides FOI
were employed. Therefore, the purpose of this study was to
establish a novel quantitative readout for ICG-enhanced
FOI to allow more accurate joint assessment and to
prospectively compare this imaging method with CE,
US, and contrast enhanced 1.5 T MRI for detection of
inflamed and non-inflamed joints of the hands in patients
with proven RA.
Methods
Patients
Patients with known RA seeking routine clinical care and
reporting symptoms suggestive of wrist and/or finger joint
involvement were asked to participate in the study. Inclu-
sion criteria were an established diagnosis of RA according
to the American College of Rheumatology criteria from
1987, elevated rheumatoid factor (RF), and/or elevated
anti-cyclic citrullinated peptide (anti-CCP) antibodies, and
reported symptoms suggestive of wrist and/or finger-joint
involvement. Exclusion criteria were pregnancy, renalfailure, increased skin pigmentation [29], known allergy
against iodine, ICG or gadolinium, or other contraindica-
tions for MRI. The study was performed in compliance
with the Declaration of Helsinki. The study protocol was
approved by the ethics committee of the University Medical
Center Regensburg. All study participants signed consent
forms after receiving appropriate written and oral infor-
mation prior to enrollment.
Demographical data (sex, age, disease duration) and
laboratory data (RF, anti-CCP, serum C reactive protein
(CRP) and erythrocyte sedimentation rate (ESR)) were
derived by chart review. All patients received a standardized
rheumatologic CE of the 28 joints included in the Disease
Activity Score 28 (DAS28, [30]) by one of the authors
(V.S. or W.H.) using a bimanual technique, documenting
tender and swollen status for each joint. The DAS28 was
calculated for each patient [30].
All data regarding clinical and imaging studies were
obtained within two days after inclusion for each enrolled
patient.
Ultrasonography
The joints included in the US7 score (wrist, metacarpo-
phalangeal (MCP) and proximal interphalangeal (PIP)
joints of the index (II) and middle (III) finger of the clinic-
ally dominant hand, and the metatarsophalangeal (MTP)
joints of the second (II) and fifth (V) toe of the clinical
predominant foot) were examined by ultrasonography by
one of the authors (V.S. or W.H.) using a LOGIQ E9
(GE, Munich, Germany) ultrasound machine with a linear
transducer (ML 6–15) with 15 MHz frequency [31]. Each
joint was rated separately semiquantitatively (grades 0 to
3) for distension of the capsule due to synovitis with grey
scale ultrasonography (GSUS) and for synovial vascularity
with color Doppler ultrasonography (CDUS). The presence
of synovitis was concluded for each mode if at least grade
1 findings were observed. For each patient the US7 score
was calculated [31].
Magnetic resonance imaging
For each patient a gadolinium-enhanced MRI of the clinic-
ally dominant hand was performed using a 1.5 T high-field
MR scanner. The main focus of the MRI examination was
the evaluation of the carpal and MCP joints, and if included
in the examination field also the evaluation of the PIP
joints. The examination protocol was performed analog to
routine clinical practice and in line with the recommenda-
tions of the RAMRIS (Rheumatoid Arthritis MRI Scoring
system) [32]. Fat saturated proton or T2-weighted and
contrast-enhanced T1-weighted sequences were used in
at least one coronal and axial plane. Additional unenhanced
T1-weighted sequences were acquired in coronal plane.
One of the 18 patients was examined with fat saturated
proton-weighted and T2-weighted sequences, and the other
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images. For all patients the contrast-enhanced T1-weighted
images were fat saturated using spectral saturating tech-
nique. Gadoteric acid (Dotarem®, Guerbet, Villepinte, France)
was applied as intravenous contrast agent using a dosage of
0.2 ml/kg. (The majority of patients were examined using
the following MRI protocol: prone position with the hand
placed over the head in an extremity surface flex coil, cor-
onal fat saturated proton-weighted turbo spin echo (Cor PD
TSE fs), echo time (TE) 29/repetition time (TR) 2260, slice
thickness (ST) 2.5 mm, gap 0.25 mm, field of view (FOV)
240 × 320 mm2, scan time: 1 minute 40 seconds. Sagittal fat
saturated proton-weighted turbo spin echo (Sag PD TSE fs),
TE 29/TR 3630, ST 3 mm, gap 0.3 mm, FOV 240 × 320
mm2, scan time: 1 minute 45 seconds. Coronal T1-weighted
turbo spin echo (Cor T1 TSE), TE 14/TR 586, ST 2.5 mm,
gap 0.25 mm, FOV 256 × 320 mm2, scan time: 2 minutes 16
seconds. Axial contrast-enhanced T1-weighted fat saturated
turbo spin echo (Axial CE T1 TSE fs), TE 14/TR 732, ST 2.5
mm, gap 0.25 mm, FOV 236 × 192 mm2, scan time: 1
minute 40 seconds.) All MRI scans were read according to
the RAMRIS scoring system by an experienced radiologist
(P.H., seven years of MRI experience) blinded to clinical and
ultrasonography data. The presence of synovitis was con-
cluded for each joint, if at least grade one findings were ob-
served. Additionally, the extensor tendons overlying the
joint were evaluated for the presence of tenosynovitis. The
RAMRIS score has been calculated for each patient.Fluorescence optical imaging
A commercially available, near-infrared fluorescence
imaging system (Xiralite X4, Mivenion GmbH, Berlin,
Germany) was used in this study. The working principle
is based on the excitation of ICG dye by light emitting
diodes and the detection of fluorescence signals with a
sensitive camera. The instrument is controlled by a com-
plementary PC and records image sequences with a stan-
dardized frame rate of one frame (image) per second over
a period of six minutes. Thus, a stack of 360 images is
provided for each individual examination.
The FOI examination followed a standardized procedure:
both hands were placed on a preformed hand rest. Ten
seconds after starting the examination, an ICG bolus (0.1
mg/kg) was injected manually in the cubital vein over the
period of approximately one second (ICG-Pulsion, Pulsion,
Feldkirchen, Germany). Any alteration of fluorophor con-
centration can be depicted as alteration of signal intensity.
Due to hepatic clearance of ICG, FOI signals decay with a
time constant of typically three to four minutes. In a pilot
study, it was found that the relative FOI signal intensities
within one frame do not change significantly after an
imaging period of six minutes. Therefore, this duration
was determined as the standard examination time.FOI findings were analyzed using software provided
by the manufacturer (Xiralyze (version 1.0.3), Mivenion
GmbH, Berlin, Germany). Electronically generated compos-
ite images (CI) were calculated from the mean fluorescence
signal intensities of an image stack of sequential subsets of
acquired images. In line with two previous publications,
we defined CI for three sequential phases with a duration
of 120 seconds each (1 to 120 seconds, 121 to 240 seconds,
and 241 to 360 seconds) [8,19]. To allow for quantitative
assessment, five joints (wrist, MCP II and III, and PIP
II and III) of each patient were analyzed using circular
regions of interest (ROI), with the size of each ROI defined
according to the anatomical size of the corresponding joint
(a diameter of 22 pixel for wrists, 12 pixel for MCP- and
10 pixel for PIP-joints; see Figure 1). The resulting fluores-
cence readout (FLRO) represents, therefore, the mean
fluorescence intensity per pixel of the analyzed CI.
To evaluate the influence of the general perfusion of
the whole hand on the readout of individual joints, an
additional analysis method was developed: the FLRO at
the eponychium of the index finger was determined in each
patient, an anatomical site not known to be involved in
inflammatory processes in patients with RA (using a
circular ROI with a diameter of five pixel, placed centrally
over the eponychium). In order to standardize individual
joint FOI readout results for the general perfusion, we
established a fluorescence ratio (FLRA) for each joint by
dividing the readout of the joint ROI by the readout of the
eponychium of the index finger.
Statistical analysis
Data evaluation and statistical analyses were performed
using SPSS software (version 20, IBM, Ehningen, Germany).
We compared the mean FLRO and mean FLRAs of joints
with compared with those without evidence of synovitis
derived by clinical evaluation (tender or swollen joints) or
by established imaging techniques (GSUS, CDUS, MRI)
for all three phases and the sum of the three phases using
Student’s t-test statistic. Statistical significance was con-
cluded when two-sided P values were below 0.05.
Results
The study population included 18 subjects, eight women
(44%) and 10 men (56%), with a mean (± standard deviation
(SD)) age of 63.0 (± 10.0) years. All subjects tolerated
the procedure well, and no adverse events were observed.
Patient’s clinical and laboratory characteristics, and US
and MRI scores are displayed in Table 1. To illustrate the
comparison of the employed imaging methods, Figure 2
displays the carpal arthritis of a 50-year-old subject
with RA.
A total of 90 joints from the 18 patients were analyzed
(18 carpal, 36 MCP, and 36 PIP joints). All 90 joints were
evaluated by CE and US and 79 by MRI. The CE revealed
Figure 1 FOI images of a female RA patient. Fluorescence optical imaging composite images of the hands of a female patient with
rheumatoid arthritis: (A) phase 1 (1 to 120 seconds); (B) phase 2 (121 to 240 seconds), and (C) phase 3 (241 to 360 seconds). Depicted are the
placement of the regions of interest for the carpal, metacarpalphalangeal (MCP), and proximal interphalangeal (PIP) joint of the index (II) and
middle (III) fingers and the control region at the eponychium of the index finger (white arrow).
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tender joints (TJ). The GSUS revealed 39 of 90 (43%),
CDUS revealed 23 of 90 (26%) and MRI revealed 39 of
79 (49%) joints that displayed findings consistent with
active synovitis. Four of the 79 joints (5%) evaluated by
MRI also displayed tenosynovitis of the overlying extensor
tendons, but in all four instances the adjoining joint also
showed signs of synovitis.
The quantitative analysis for individual joints of the FLRO
yielded values ranging from 4.4 to 49.0 × 103 (mean 19.1 ±
SD 9.5) for phase 1, 4.2 to 47.9 × 103 (mean 19.6 ± SD 9.2)
for phase 2, and 2.6 to 40.9 × 103 (mean 12.8 ± SD 6.8)
for phase 3. The results of the quantitative analysis of
the FOI data are displayed in Table 2. The comparison
yielded significant differences of the mean FLRO between
joints with compared to those without evidence of active
synovitis determined by US and MRI, but not by CE. Of
note, there were significant differences of the mean FLRO
between joints with compared to those without synovitis
determined by GSUS and MRI for phases 2 and 3, whereas
significant differences have been only observed by CDUS
in phases 1 and 2.Table 1 Patient characteristics and results of laboratory
and imaging studies*
All patients, n (%) 18 (100%)
Male, n (%) 10 (56%)
Female, n (%) 8 (44%)
Age 63.0 ± 10.0 years
Disease duration 4.9 ± 4.4 years
ESR 25.4 ± 25.3 mm/hour
CRP 17.2 ± 19.6 mg/l
CE, tender joints 7.3 ± 5.0
CE, swollen joints 5.4 ± 5.4
Disease activity (DAS28) 4.6 ± 1.6
Ultrasonography score (US7) 13.8 ± 9.4
MRI score (RAMRIS) 14.6 ± 10.0
*Except where indicated otherwise, values are the mean ± SD. CE clinical
examination, CRP C-reactive protein, DAS28 disease activity score of 28 joints,
ESR erythrocyte sedimentation rate, MRI magnetic resonance imaging.To dissect the effect of the overall perfusion of the
hand from the perfusion due to active synovitis and to
improve FOI results, novel FLRA scores were calculated
for each individual joint as described above. The FLRO
at the eponychium of the index finger ranged from 8.6
to 42.2 × 103 (mean 20.8 ± SD 9.5) for phase 1, 5.5 to
36.0 × 103 (mean 16.8 ± SD 7.7) for phase 2, and 3.1 to
25.3 × 103 (mean 10.7 ± SD 5.4) for phase 3. The derived
values of the FLRAs ranged from 0.37 to 2.27 (mean
0.97 ± SD 0.39) for phase 1, 0.60 to 2.88 (mean 1.20 ± SD
0.39) for phase 2, and 0.62 to 2.87 (mean 1.23 ± SD 0.39)
for phase 3. The results of the FLRAs are displayed in
Table 3. Compared with the analysis of the FLRO, the
FLRA results demonstrated improved discrimination
between joints with compared with those without evidence
of active synovitis resulting in significant differences of
the calculated FLRA values compared with all clinical
and imaging techniques in phases 2 and 3. Additionally,
analyses comparing FOI with MRI stratified by joint type
(carpal, MCP, PIP) were performed (data not shown). Due
to the fact that 15 of 18 carpal joints displayed synovitis
by MRI, no statistical significant differences were found for
FLRO and FLRA for this subgroup analysis. The subgroup
analyses of MCP and PIP joints revealed similar findings
to the analysis of all joints, with better discrimination of
FLRA than FLRO in both subgroups.
A receiver-operating characteristic analysis, comparing
the FLRAs of phase 1, phase 2, and phase 3 to detect
synovitis confirmed by MRI as gold standard revealed
the highest area under the curve for phase 3 (0.67), whereas
lower values have been observed for phase 1 (0.58) and
phase 2 (0.65). Using a cut-off value for the FLRA of phase
3 of more than 1.2 to detect MRI-confirmed synovitis with
FOI, a sensitivity of 26 of 39 (67%; 95% confidence interval
(CI), 51 to 79%) and a specificity of 31 of 40 (77%; 95% CI,
62 to 88%) were calculated, with a sensitivity of 21 of 32
(66%; 95% CI, 48 to 80%) for grade 1, and five of seven
(71%; 95% CI, 36 to 92%) for grade 2 and 3 MRI-detected
synovitis. A stratified analysis by joint type utilizing the
same cut-off for FLRA of phase 3 to detect synovitis
confirmed by MRI revealed a sensitivity/specificity of
Figure 2 Correlation of FOI with CDUS and MRI. Comparison of the fluorescence optical imaging (FOI) composite image (A) of phase 2 (121 to
240 seconds) with (B) color Doppler ultrasonography (CDUS; showing effusion with hyperperfusion) and (C) magnetic resonance imaging (MRI;
contrast-enhanced T1-weighted transverse view displaying grade 2 synovitis) of a 50-year-old male patient with carpal arthritis of the right hand.
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Table 2 Mean fluorescence readout for joints with compared to those without evidence of synovitis determined by
clinical examination or established imaging techniques #
FOI phase 1
(1 – 120 seconds)
FOI phase 2
(121 – 240 seconds)
FOI phase 3
(241 – 360 seconds)
Synovitis n mean ± SD P mean ± SD P mean ± SD P
TJ yes 44 19.1 ± 11.0 ns 19.6 ± 9.0 ns 12.6 ± 5.7 ns
TJ no 46 19.2 ± 7.8 19.6 ± 9.4 13.0 ± 7.8
SJ yes 26 22.7 ± 12.6 ns 22.3 ± 9.8 ns 14.1 ± 6.2 ns
SJ no 64 17.7 ± 7.5 18.5 ± 8.7 12.3 ± 7.0
GSUS yes 39 21.0 ± 11.4 ns 23.5 ± 10.4 ** 15.8 ± 7.9 **
GSUS no 51 17.7 ± 7.5 16.6 ± 6.8 10.5 ± 4.8
CDUS yes 23 24.1 ± 12.3 * 23.8 ± 9.3 * 15.0 ± 5.9 ns
CDUS no 67 17.5 ± 7.7 18.2 ± 8.7 12.0 ± 7.0
MRI yes 39§ 20.9 ± 10.1 ns 22.3 ± 9.5 * 14.8 ± 7.3 *
MRI no 40§ 17.8 ± 9.6 17.2 ± 9.2 10.9 ± 6.5
All 90 19.1 ± 9.4 19.6 ± 9.2 12.8 ± 6.8
# Fluorescence readout results are displayed for better readability divided by 103; § 11 joints could not be evaluated with MRI; * P<0.05; ** P<0.01.
CDUS color Doppler ultrasonography, FOI fluorescence optical imaging, GSUS grey-scale ultrasonography, MRI magnetic resonance imaging; ns, comparison was
not significant (P≥0.05 with student’s t-test), SD standard deviation, SJ swollen joint by clinical examination, TJ tender joint by clinical examination.
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joints, 42% (95% CI, 23 to 62%)/93% (95% CI, 70 to 99%)
for MCP joints, and 100% (95% CI, 57 to 100%)/77% (95%
CI, 57 to 90%) for PIP joints.
Discussion
FOI with the Xiralite system is an emerging imaging
technology. However, so far only semiquantitative analyses
of FOI results have been reported limiting the strength
and reliability of this method. Therefore, we aimed to es-
tablish a novel scoring system to allow for a quantitativeTable 3 Mean fluorescence ratios (standardized for overall pe
without evidence of synovitis determined by clinical examina
Ratio FOI phase 1
(1 – 120 seconds)
Synovitis n Mean ± SD P
TJ yes 44 1.02 ± 0.45 ns
TJ no 46 0.93 ± 0.33
SJ yes 26 1.13 ± 0.50 *
SJ no 64 0.91 ± 0.33
GSUS yes 39 1.06 ± 0.47 ns
GSUS no 51 0.91 ± 0.32
CDUS yes 23 1.22 ± 0.46 **
CDUS no 67 0.89 ± 0.33
MRI yes 39§ 1.11 ± 0.46 **
MRI no 40§ 0.86 ± 0.33
All 90 0.97 ± 0.39
# Fluorescence ratios were derived by dividing the readout of each joint by the rea
could not be evaluated with MRI; * P<0.05; ** P<0.01; *** P<0.001.
CDUS, color Doppler ultrasonography; FOI, fluorescence optical imaging; GSUS, grey
not significant (P≥0.05 with student’s t-test); SD, standard deviation; SJ, swollen joinFOI analysis: introducing and defining circular ROIs for
five joints (wrist, MCP II and III, and PIP II and III) FLROs
could be calculated representing the mean fluorescence in-
tensity per pixel of the analyzed CI. In order to standardize
the quantitative analysis for each patient individually,
the FLRO at the eponychium of the index finger has been
determined in each patient as a marker of the general per-
fusion. Dividing the readout of the joint ROI by the readout
of the eponychium of the index finger, FLRAs could be
calculated for each joint allowing quantitative analysis of
FOI results in each patient individually. To validate therfusion of the hand) for joints with compared with those
tion or established imaging techniques #
Ratio FOI phase 2
(121 – 240 seconds)
Ratio FOI phase 3
(241 – 360 seconds)
Mean ± SD P Mean ± SD P
1.31 ± 0.48 * 1.33 ± 0.48 *
1.10 ± 0.23 1.13 ± 0.24
1.43 ± 0.54 ** 1.45 ± 0.54 **
1.11 ± 0.26 1.14 ± 0.26
1.33 ± 0.48 * 1.37 ± 0.48 **
1.10 ± 0.26 1.12 ± 0.26
1.52 ± 0.52 ** 1.53 ± 0.53 **
1.09 ± 0.26 1.12 ± 0.26
1.38 ± 0.47 *** 1.41 ± 0.46 ***
1.06 ± 0.26 1.08 ± 0.26
1.20 ± 0.39 1.22 ± 0.39
dout of the control area of the eponychium of the index finger; § 11 joints
-scale ultrasonography; MRI, magnetic resonance imaging; ns, comparison was
t by clinical examination; TJ, tender joint by clinical examination.
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(GSUS, CDUS, and MRI) as well as CE were applied to
compare differentiation of joints with and joints without
evidence of synovitis. To our knowledge this is the first
study evaluating the ability of this novel imaging modality
comparing quantitative fluorescence readout to synovitis
detected by MRI and US.
In arthritic conditions, angiogenesis is highly dysregulated
[33]. Furthermore, hypervascularisation and angiogenesis
of the synovial membrane are a hallmark in RA patients
[34] and strongly linked to bone destruction. The degree
of synovial vascularisation correlates well with the disease
activity of a given joint [35,36], as well as radiographic
progression [37] and with the therapeutic response in
patients with RA [38]. Therefore, FOI might be a useful tool
to detect and monitor disease activity in RA patients by
visualization of microperfusion changes in affected joints.
Using the quantitative approach for the evaluation of
the obtained FOI results, significant differences of the
mean FLRO have been observed between synovitic and
non-synovitic joints for the results of phases 2 and 3,
which were even more striking after standardization by
calculating the FLRAs. Unfortunately, no definite cut-off
values for perfect separation of synovitic from non-
synovitic joints could be established in our pilot study.
However, a sensitivity of 67% and a specificity of 77% was
calculated using a cut-off value for the FLRAs of phase 3
of more than 1.2 to detect MRI-confirmed synovitis with
FOI, which demonstrates the diagnostic yield of this novel
imaging method. The subgroup analyses stratified by joint
type revealed for this cut-off a higher sensitivity for carpal
and PIP joints than for MCP joints. Larger future studies
should address if different joint types deserve distinct
cut-offs for FLRA interpretation.
In each FOI sequence, three phases were scaled, giving
different results in comparison to the other imaging
modalities. In the publication by Werner et al. [8] phase
1 displayed the highest agreement with CE and CDUS,
whereas the highest sensitivity was observed in phase 2,
comparable with the sensitivity of US in relation to MRI.
Using MRI as standard of reference, the FOI system
displayed a sensitivity of 76% and a specificity of 54%
using different analysis parameters. Consistent to these
findings, a sensitivity of 67% and a specificity of 77% were
calculated for FOI in our study compared with MRI
findings. With regard to the different phases analyzed,
our results differ partially to the previous observations,
as phase 1 did not show similar significant results,
whereas phases 2 and 3 correlated best with all imaging
modalities following standardization.
In a recent study by Meier et al. [19], FOI was compared
with CE and three T-weighted MRI. Using MRI as stand-
ard of reference, FOI displayed a sensitivity of 39.6% and a
specificity of 85.2%. In that study, the diagnostic accuracyof the FOI was altogether lower and particularly limited in
mild synovitis, whereas it performed substantially better
in severely inflamed joints.
So far, different methods for interpreting the FOI results
have been deployed [8,19,28]. Werner et al. [8] used a
semiquantitative score, where the signal enhancement has
been graded in percentages. In contrast, Meier et al. [19]
utilized a semiquantitative assessment where synovitis was
graded in each joint ranging from 0 to 3. As outlined by
these investigators, a semiquantitative approach revealed
only moderate interreader agreement with poor findings
for the PIP and DIP joints, respectively [19]. Although
we did not test for interreader agreement formally, our
quantitative approach using directly computed FLRO and
FLRA circumvents these problems of semiquantitative
analyses.
In their study, Dziekan et al. used a ROI placed over
the corresponding finger nail to standardize the FLRO
of each finger joint to the interpersonal changes of
overall perfusion [28]. Their quantitative analyses were
not stratified into the three phases, as employed in our
and other studies [8,19,28]. The authors noted that
with their proposed method of quantitative FOI ana-
lysis a good separation between asymptomatic and
inflamed joints (delineated by clinical examination of
patients with RA) was not possible. They mainly attributed
that finding to the lack of a ‘gold standard’, because no
other imaging methods (e.g. US or MRI) were employed
in their study.
Werner et al. utilized the percentage of surface area of
the affected joint to arrive at a ordinal scale from 0 to 3,
whereas the publication by Meier et al. used the criteria
of the RAMRIS semiquantitative scoring system [32],
developed to evaluate synovitis detected by MRI, also
for semiquantitative interpretation of the FOI data [8,19].
Both approaches are based on changes of fluorescence
intensity of the joint of interest compared with the
fluorescence in unaffected joints over time, and are there-
fore not prone to be affected strongly by the background
change of increasing and then decreasing concentrations
of ICG. This difference of ICG concentrations during the
three phases may explain why FLRA displayed a better
discrimination between inflamed and non-inflamed joints
then the plain FLRO results.
We are aware of some limitations concerning the
image interpretation and quantification of pathological
changes. Although the FOI procedure itself is standardized,
consistent standards for image adjustment and automated
interpretation are not yet established. We have chosen
to set ROIs over those finger joints, which are typically
involved in RA. This allows for better quantitative
examination, but each ROI has to be set manually and
the radius of the different ROIs needs still to be more
accurately defined.
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Our pilot study demonstrates that a quantitative assessment
of the fluorescence results obtained by FOI is feasible, al-
though so far no definite cut-off value could be delineated
that perfectly separates inflamed from non-inflamed joints
in patients with RA. Based on the better discrimination of
FLRA compared with FLRO we postulate to use FLRA in
larger studies to further set and evaluate the diagnostic
yield of quantitative interpretation of FOI in the clinical
care of patients with suspected or established RA.
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